Logo 1200x628.jpg
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
November 07, 2024 16:05 ET | CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 1200x628.jpg
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
November 04, 2024 07:00 ET | CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
Logo 1200x628.jpg
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
October 22, 2024 07:00 ET | CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
Logo 1200x628.jpg
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
October 17, 2024 07:00 ET | CytoSorbents
CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024
Logo 1200x628.jpg
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
October 01, 2024 07:00 ET | CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
Logo 1200x628.jpg
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
August 07, 2024 07:00 ET | CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
Logo 1200x628.jpg
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
August 01, 2024 07:00 ET | CytoSorbents
CytoSorbents regains compliance with Nasdaq minimum bid price requirement
Logo 400x400.jpg
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
May 02, 2024 07:00 ET | CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
Logo 400x400.jpg
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
April 17, 2024 07:00 ET | CytoSorbents
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Logo 400x400.jpg
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
December 28, 2023 07:00 ET | CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation